Cambridge Heart, Inc. Release: Microvolt T-Wave Alternans Found to Be Highly Accurate Predictor of Arrhythmic Events in Meta-Analysis of 6,000 Patients

TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), today announced that a meta-analysis of Microvolt T-Wave Alternans (MTWA) studies was presented by Dr. Stefan Hohnloser at the Heart Rhythm Society 2008 Scientific Sessions in San Francisco. The study entitled “Predictive Accuracy of Microvolt T-Wave Alternans Testing in Primary Prevention Patients With and Without ICDs” analyzed 14 recent trials, which collectively enrolled approximately 6,000 patients.
MORE ON THIS TOPIC